Skip to main content

Table 1 The difference in development cohort and the validation cohort in terms of the demographic characteristics, laboratory values

From: Development and validation of short-term renal prognosis prediction model in diabetic patients with acute kidney injury

Parameters

Total

Development cohort

Validation cohort

t/χ2

P-value

Male/female

624/292

435/206

189/86

0.066

0.797

Age (year)

61.31 ± 13.40

61.13 ± 13.21

61.75 ± 13.85

− 0.642

0.521

Length of stay (day)

25.66 ± 51.77

20.39 ± 16.97

21.39 ± 18.21

− 0.723

0.470

Diabetes duration (month)

43.18 ± 24.77

44.78 ± 26.14

39.98 ± 21.48

2.920

0.004

Hypertension [n(%)]

566 (61.8)

393 (61.3)

173 (62.9)

0.208

0.648

CKD [n(%)]

364 (39.7)

258 (40.2)

106 (38.5)

0.233

0.629

BMI (kg/m2)

24.04 ± 3.71

23.80 ± 3.86

24.16 ± 4.24

− 1.063

0.288

PP (mmHg)

58.62 ± 18.38

57.83 ± 18.38

59.51 ± 17.70

− 1.273

0.203

MAP (mmHg)

95.79 ± 17.24

95.64 ± 18.17

96.90 ± 17.05

− 0.971

0.332

WBC (×109/L)

12.51 ± 7.68

12.63 ± 8.13

12.21 ± 6.52

0.782

0.434

Hb (g/L)

104.06 ± 23.28

104.56 ± 23.11

102.90 ± 23.67

0.934

0.350

PLT (×109/L)

191.55 ± 86.90

189.51 ± 82.64

196.32 ± 96.15

− 1.024

0.306

Alb (g/L)

32.27 ± 7.16

32.20 ± 7.94

31.96 ± 7.71

0.393

0.695

25(OH)D3 (nmol/L)

57.23 ± 23.29

57.36 ± 23.65

56.92 ± 22.47

0.265

0.791

NT-proBNP (pg/mL)

3632.98 ± 1851.39

4122.55 ± 1701.35

4017.90 ± 1422.01

0.880

0.379

FBG (mmol/L)

8.39 ± 2.94

8.46 ± 3.49

8.22 ± 3.42

0.834

0.405

PBG (mmol/L)

12.44 ± 2.80

12.41 ± 3.95

12.34 ± 4.15

0.170

0.865

HbA1c (%)

7.52 ± 1.36

7.49 ± 1.62

7.48 ± 1.74

0.102

0.918

BUN (mmol/L)

13.89 ± 8.85

14.00 ± 9.97

14.15 ± 10.28

− 0.194

0.846

Baseline Scr (µmol/L)

132.53 ± 102.00

141.09 ± 116.94

149.80 ± 139.41

− 0.798

0.425

UA (µmol/L)

422.60 ± 196.55

418.43 ± 197.07

410.48 ± 203.23

0.540

0.589

HCO3− (mmol/L)

22.04 ± 5.23

22.13 ± 5.18

21.82 ± 5.36

0.807

0.420

Cystatin C (mg/L)

2.31 ± 1.45

2.35 ± 1.49

2.24 ± 1.36

1.011

0.312

Serum potassium (mmol/L)

4.19 ± 0.81

4.20 ± 0.81

4.17 ± 0.81

0.492

0.623

AKI stage

   

3.074

0.215

 1

402 (43.9)

273 (42.6)

129 (46.9)

  

 2

337 (36.8)

235 (36.7)

102 (37.1)

  

 3

177 (19.3)

133 (20.7)

44 (16.0)

  

Discharged Scr (µmol/L)

215.17 ± 160.55

217.02 ± 160.71

210.88 ± 160.38

0.530

0.596

RRT [n(%)]

186 (20.3)

140 (21.8)

46 (16.7)

3.110

0.078

Renal recovery

304 (33.2)

224 (34.9)

80 (29.1)

2.975

0.085

  1. 25(OH)D3 25-hydroxyvitamin D3; AKI acute kidney injury; Alb albumin; BMI body mass index; BUN blood urea nitrogen; CKD chronic kidney disease; FBG fasting blood glucose; Hb hemoglobin; HbA1c hemoglobin A1c; MAP mean arterial pressure; NT-proBNP N-terminal prohormone of brain natriuretic peptide; PBG postprandial blood glucose; PLT platelet count; PP pulse pressure; RRT renal replacement therapy; Scr Serum creatinine; UA uric acid; WBC white blood cell count
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us